JL
Therapeutic Areas
Lipigon Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lipisense | Severe Hypertriglyceridemia (SHTG) / Dyslipidemia | Phase II |
| Dyslipidemia (Small Molecule LPL Activator) | Dyslipidemia / Cardiovascular Risk | Preclinical |
| CAP (ANGPTL4 ASO) | Community-Acquired Pneumonia (CAP) / ARDS Prevention | Preclinical |